reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-19. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Freight technology in air cargo is already critically important in cold chain management for sensitive goods such as agricultural products, vaccines, and medications. Monitoring in the form of data loggers can record temperature, light, humidity, and GPS location to show whether goods have been improperly cooled, handled, or tampered with. It is estimated that billions of dollars in revenue are lost by cargo companies annually due to dispute resolution for shipment delays and lost and damaged goods. The world’s first blockchain-based system for streamlining air cargo costing, billing, and reconciliation was announced at the 2019 IATA World Cargo Symposium.
== Fictional background == In Eiichiro Oda's One Piece series, each pirate crew has its own distinct Jolly Roger that reflects its traits and beliefs. Although the flag was originally drawn by the main series protagonist Monkey D. Luffy, his poor sketch led one of his crewmates Usopp to redesign it. One Piece itself is one of the longest-running and most popular Japanese media franchises, its manga (beginning publication in 1997) being the best-selling of all time and its anime running since 1999. The flag's anti-authoritarian usage is a reference to a major storyline involving the fictional world government, which controls most of the story's locations, and the Straw Hat Pirates' struggles to fight back, while concurrently hunting for the titular treasure. As described by CNN, "the flag symbolizes Luffy's quest to chase his dreams, liberate oppressed people, and fight the autocratic World Government". Multiple academic works have analysed how the manga draws parallels to real world politics and authoritarianism.
== Vaccine == No vaccine for syphilis is currently available, but doxycycline postexposure prophylaxis can be used to prevent infections. The outer membrane of T. pallidum has too few surface proteins for an antibody to be effective.The outer membrane of T. pallidum has very few confirmed surface-exposed proteins, which due to the organism's elaborate biology and slow growth, has hindered progress towards the development of an effective syphilis vaccine. In contrast, some of the antigenic targets of T. pallidum are located in the periplasmic space or inner membrane, rather than being fully surface-exposed, which limits antibodies' effectiveness when trying to clear the infection. In the last century, several prototypes have been developed, and while none of them provided protection from the infection, some prevented bacteria from disseminating to distal organs and promoted accelerated healing.
Sources: en.wikipedia.org
Kilishi – a version of biltong or jerky that originated in Hausaland, it is a delicacy made from cow, sheep or goat meat after the removal of bone. Kuivaliha – salted and dried meat, often reindeer meat, is a traditional food and a delicacy of northern Finland, prepared at springtime. Kulen – a kind of highly spiced, semi-dried, smoked, cured sausage from Croatia (Slavonia) and Serbia (Vojvodina). The meat undergoes fermentation-curing as well as the air-drying.
Certain inks, coatings, and adhesives are formulated with photoinitiators and resins. When exposed to UV light, polymerization occurs, and so the adhesives harden or cure, usually within a few seconds. Applications include glass and plastic bonding, optical fiber coatings, the coating of flooring, UV coating and paper finishes in offset printing, dental fillings, hydrophobic light-activated adhesive, and decorative fingernail "gels". UV sources for UV curing applications include UV lamps, UV LEDs, and excimer flash lamps. Fast processes such as flexo or offset printing require high-intensity light focused via reflectors onto a moving substrate and medium so high-pressure Hg (mercury) or Fe (iron, doped)-based bulbs are used, energized with electric arcs or microwaves. Lower-power fluorescent lamps and LEDs can be used for static applications. Small high-pressure lamps can have light focused and transmitted to the work area via liquid-filled or fiber-optic light guides. The impact of UV on polymers is used for modification of the (roughness and hydrophobicity) of polymer surfaces. For example, a poly(methyl methacrylate) surface can be smoothed by vacuum ultraviolet. UV radiation is useful in preparing low-surface-energy polymers for adhesives. Polymers exposed to UV will oxidize, thus raising the surface energy of the polymer. Once the surface energy of the polymer has been raised, the bond between the adhesive and the polymer is stronger.
These cells generate action potentials that propagate down axons to the nerve endings in the pituitary; the endings contain large numbers of oxytocin-containing vesicles, which are released by exocytosis when the nerve terminals are depolarised.
Magnetic nanoparticle drug delivery is the use of external or internal magnets to increase the accumulation of therapeutic elements contained in nanoparticles to fight pathologies in specific parts of the body. It has been applied in cancer treatments, cardiovascular diseases, and diabetes. Scientific researches revealed that magnetic drug delivery can be made increasingly useful in clinical settings.
Sources: en.wikipedia.org
In Indonesia, the hardline anti-communist General Suharto wrested control from predecessor Sukarno in an attempt to establish a "New Order". From 1965 to 1966, with the aid of the US and other Western governments, the military led the mass killing of more than 500,000 members and sympathizers of the Indonesian Communist Party and other leftist organizations, and detained hundreds of thousands in prison camps under inhumane conditions. A top-secret CIA report stated that the massacres "rank as one of the worst mass murders of the 20th century, along with the Soviet purges of the 1930s, the Nazi mass murders during the Second World War, and the Maoist bloodbath of the early 1950s." These killings served US interests and constitute a major turning point in the Cold War as the balance of power shifted in Southeast Asia.
December 12, 2008: Russia Andrei Klepach, a deputy economics minister of Russia, states that Russia has entered the recession, with two quarters of contraction expected, meaning Russia will fall short of reaching the 6.8% growth forecast for 2008.
There are several historical accounts of people who probably had MS and lived before or shortly after the disease was described by Charcot. A young woman called Halldora who lived in Iceland around 1200 suddenly lost her vision and mobility but recovered them seven days after. Saint Lidwina of Schiedam (1380–1433), a Dutch nun, may be one of the first clearly identifiable people with MS. From the age of 16 until her death at 53, she had intermittent pain, weakness of the legs and vision loss: symptoms typical of MS. Both cases have led to the proposal of a "Viking gene" hypothesis for the dissemination of the disease. Augustus Frederick d'Este (1794–1848), son of Prince Augustus Frederick, Duke of Sussex and Lady Augusta Murray and a grandson of George III of the United Kingdom, almost certainly had MS. D'Este left a detailed diary describing his 22 years living with the disease. His diary began in 1822 and ended in 1846, although it remained unknown until 1948. His symptoms began at age 28 with a sudden transient visual loss (amaurosis fugax) after the funeral of a friend. During his disease, he developed weakness in the legs, clumsiness of the hands, numbness, dizziness, bladder disturbance and erectile dysfunction. In 1844, he began to use a wheelchair. Despite his illness, he kept an optimistic view of life. Another early account of MS was kept by the British diarist W. N. P. Barbellion, pen name of Bruce Frederick Cummings (1889–1919), who maintained a detailed log of his diagnosis and struggle. His diary was published in 1919 as The Journal of a Disappointed Man.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The dry powder is normally kept at -20 °C, protected from light and moisture. Reconstituted solutions are often divided into aliquots and stored at -80 °C to reduce freeze-thaw damage.